Recent Updates
Recently added Catalysts
VTGN Positive Sentiment Score: 70/100

VistaGen Therapeutics to Report Fiscal Year 2022 Third Quarter Financial Results on February 10, 2022

Monday, February 7, 2022 2 min read
Key Takeaway: VistaGen Therapeutics will hold a conference call on February 10, 2022, to report its financial results for the third quarter of fiscal year 2022. The call will review recent accomplishments and outline anticipated milestones. Investors and media can participate via a live audio webcast or telephone. The company focuses on developing innovative treatments for CNS disorders.

Market Sentiment Analysis

POSITIVE FACTORS

  • VistaGen is committed to innovative medicines for CNS disorders.
  • The upcoming conference call will provide insights into financial results and milestones.
  • The company has a differentiated profile for its CNS drug candidates.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) --VistaGen Therapeutics, Inc.(NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (CNS) disorders, will host a conference call and webcast on Thursday, February 10, 2022 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report its financial results for its fiscal year 2022 third quarter ended December 31, 2021 and provide a review of recent accomplishments and anticipated upcoming milestones.
Event:VistaGen Therapeutics Fiscal Year 2022 Third Quarter Financial Results Conference Call and WebcastDate:Thursday, February 10, 2022Time:2:00 p.m. Pacific Time (5:00 p.m. Eastern Time)US Dial-in (Toll Free):1-877-407-9716TOLL/International Dial-in:1-201-493-6779Conference ID:13726261Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1523673&tp_key=49008240c8
A live audio webcast of the conference call will also be available via the link provided above.  Participants should access this webcast site 10 minutes before the start of the call. In addition, a telephone playback of the call will be available after approximately 8:00 p.m. Eastern Time on Thursday, February 10, 2022.  To listen to the replay, call toll free 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally (toll). Please use the replay PIN13726261. An archived webcast will be available on VistaGen’s website following the call.
About VistaGenVistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three CNS drug candidates has a differentiated profile and therapeutic potential in multiple CNS markets. For more information, please visitwww.VistaGen.comand connect with VistaGen on Twitter, LinkedIn, and Facebook.

VistaGen Company Contacts

Media:
Mark McPartlandVice President, Corporate DevelopmentPhone: (650) 577-3606Email: IR@vistagen.com
Christy CurranSam Brown Inc.Phone: (615) 414-8668Email: ChristyCurran@sambrown.com
Investors:
Mark FlatherVice President, Investor RelationsPhone: (650) 577-3617Email: IR@vistagen.com

Frequently Asked Questions

When will VistaGen report its Q3 2022 financial results?

VistaGen will report its Q3 2022 financial results on February 10, 2022.

How can I access the VistaGen conference call?

You can access the conference call via a live audio webcast or by dialing in.

What is the focus of VistaGen's drug candidates?

VistaGen's drug candidates focus on treating anxiety, depression, and other CNS disorders.

Who to contact for media inquiries at VistaGen?

Mark McPartland is the media contact for VistaGen, reachable at 650-577-3606.

Tags: VTGN Viatris Investor Conferences Healthcare VistaGen CNS disorders financial results conference call
Last updated: Feb 7, 2022